Figure 3 | Scientific Reports

Figure 3

From: Impact of Concurrent Genomic Alterations Detected by Comprehensive Genomic Sequencing on Clinical Outcomes in East-Asian Patients with EGFR-Mutated Lung Adenocarcinoma

Figure 3

Clinical response of EGFR mutated patients treated with EGFR tyrosine kinase inhibitor (EGFR-TKI). The waterfall plot shows the best percentage change in target lesions from baseline for 13 patients treated with EGFR-TKI. Red boxes indicate those patients with a higher than median mutation burden or number of genomic alterations; *indicates patients without a measurable recurrent lesion prior to EGFR-TKI use.

Back to article page